Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
L02BG04
|
| gptkbp:CASNumber |
gptkb:135463-81-9
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasInChIKey |
OBLPEUPLXAWFNA-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C17H11N5
|
| gptkbp:hasSMILES |
N#CC1=CC=C(C=C1)CC2=CN=NN2
|
| gptkbp:hasUNII |
T6X3TUEY6X
|
| https://www.w3.org/2000/01/rdf-schema#label |
135463-81-9
|
| gptkbp:IUPACName |
4-[(1H-1,2,4-triazol-1-yl)methyl]benzonitrile
|
| gptkbp:molecularWeight |
285.31 g/mol
|
| gptkbp:name |
gptkb:Letrozole
|
| gptkbp:PubChem_CID |
3902
CHEMBL716 DB01006 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedAs |
aromatase inhibitor
|
| gptkbp:usedFor |
breast cancer treatment
|
| gptkbp:bfsParent |
gptkb:Ema-502
|
| gptkbp:bfsLayer |
6
|